In cancer, a patient is considered a survivor from the time of initial diagnosis until the end of
life. With improvements in early diagnosis and treatment, the number of cancer survivors …

Anthracyclines remain an essential component of the treatment of many hematologic and
solid organ malignancies, but has important implications on cardiovascular disease …

Background: Trastuzumab is used, alone or in conjunction with standard chemotherapy, to
treat HER2-positive breast cancer (BC). Although it improves cancer outcomes, trastuzumab …

Survival in cancer is continuously improving due to evolving oncological treatment.
Therefore, cardiovascular short-term and long-term side effects gain crucial importance for …

Purpose To determine whether the 30-s sit-to-stand (30STS) test can be a valid tool for
estimating and stratifying peak oxygen uptake (VO2peak) and 6-min walking distance …

Purpose Cardiovascular disease is a competing mortality cause in hematological cancer
survivors due to toxic oncological treatment, accumulation of risk factors, and decline of …

Although shown to be effective in improving survival and quality of life in patients with
cancer, some treatments are well-known causes of cardiotoxicity, such as anthracyclines …

Purpose Exercise-based cancer rehabilitation via digital technologies can provide a
promising alternative to centre-based exercise training, but data for cancer patients and …

Background Cancer survivors are challenging patients, as they often present increased
cardiovascular risk. In this background, cardio-oncology rehabilitation frameworks for …

Background Breast cancer (BC) treatment with anthracyclines and/or anti-human epidermal
growth factor receptor-2 (HER2) antibodies is associated with an increased risk of …